
Colinz Laboratories Gears Up for Q3 Reveal on 24th January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 23 Jan 2026 • 4:37 pm
Posted by:

Colinz Laboratories' Q3 results FY26 are scheduled to be announced on 24th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Colinz Laboratories Q3 Results 2026 Preview
- Colinz Laboratories' revenue is expected to be in the range of ₹1.47 crore, a 21.29% YoY decrease.
- Profit After Tax, or PAT, is projected to fall by 65.77% YoY.
- Colinz Laboratories' EBITDA is expected to rise to ₹0.03 crore.
- Net profit is ₹0.05 crore, a fall 65.77% YoY
Colinz Laboratories Share Performance
- Over the past six months, Colinz Laboratories' share price has fallen by 7.80% to ₹1.3546.20.
- Moreover, over the past year, the stock has decreased by 12.96%.
- Despite this weak short-term performance, Colinz Laboratories' stock has delivered a financially sound 331.78% return over the past 5 years.
- As of 23rd January 2026, the stock traded at ₹46.20 per share.
Key Factors to Watch for Colinz Laboratories Q3 Results FY26
- Revenue Trend: Whether net sales decline continues or stabilizes after recent contraction.
- Profitability & Margins: Movement in PAT and operating margins amid cost pressures and shrinking top line.
- Dependence on Other Income: Extent to which non-operating income supports profits, affecting quality of earnings.
- Cash Position & Liquidity: Any change in cash reserves and working capital given the small scale of operations.
Final Thoughts
Colinz Laboratories will announce its Q3 FY26 results on 23rd January 2026. Analysts expect 21.29% YoY revenue growth, a 65.77% fall in PAT, and a 77.97% fall in EBITDA. Colinz Laboratories focuses on manufacturing, marketing and exporting a wide range of pharmaceutical formulations — including allopathic, ayurvedic and nutraceutical products in tablets, capsules, injectables, creams, syrups and related dosage forms — for various therapeutic segments like gynecology, cardiology and gastroenterology.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
Recent Articles

Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026

Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026

Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026

Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





